克里斯塞内拉分钟通过调节氨代谢来缓解乙胺诱导的肝毒性
Ting Yao1, Liyun Fu1, Youhe Wu1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City 310003, China.
克里斯森氏菌微小益生菌疗法减轻了小鼠的乙氨基诱导的肝损伤 (AILI). 它通过调节肠道微生物群和氨酸代谢来减少肝损伤标志物,炎症和氧化应激.
科学领域:
- 微生物学 微生物学
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
背景情况:
- 由于治疗选择有限,乙氨基诱导的肝损伤 (AILI) 提出了治疗挑战.
- 益生菌干预措施,如克里斯森氏菌 (C. minuta),显示在管理代谢和炎症状况方面具有潜力.
研究的目的:
- 在小鼠模型中研究C. minuta对AILI的治疗作用.
- 阐明C. minuta对AILI的保护作用背后的分子机制.
主要方法:
- 在AILI.minuta的小鼠模型中给C.minuta注射.
- 评估肝损伤标志物 (ALT,AST),氧化应激指标 (MDA,GSH/GSSG,SOD) 和炎症类细胞因子 (IL6,IL1β,TNF-α).
- 对肠道微生物群组成,氨酸代谢和相关信号通路 (PI3K-AKT,Integrin,MAPK) 的分析.
主要成果:
- C. minuta显著降低了肝损伤标志物,改善了肝脏组织病理学.
- 用C.minuta治疗减少了氧化应激和炎症.
- C. minuta调节了氨代谢,恢复了肠道微生物群的多样性,影响了MAPK通路.
结论:
- C. minuta 显示出针对 AILI 的预防和治疗潜力.
- 益生菌的益处归因于调节肠道微生物群,氨酸代谢,氧化应激和MAPK通路.
- 提升的氨酸水平被确定为加剧AILI的危险因素,可能是通过失调和代谢失调.
相关概念视频
Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...


